<code id='244B9433D2'></code><style id='244B9433D2'></style>
    • <acronym id='244B9433D2'></acronym>
      <center id='244B9433D2'><center id='244B9433D2'><tfoot id='244B9433D2'></tfoot></center><abbr id='244B9433D2'><dir id='244B9433D2'><tfoot id='244B9433D2'></tfoot><noframes id='244B9433D2'>

    • <optgroup id='244B9433D2'><strike id='244B9433D2'><sup id='244B9433D2'></sup></strike><code id='244B9433D2'></code></optgroup>
        1. <b id='244B9433D2'><label id='244B9433D2'><select id='244B9433D2'><dt id='244B9433D2'><span id='244B9433D2'></span></dt></select></label></b><u id='244B9433D2'></u>
          <i id='244B9433D2'><strike id='244B9433D2'><tt id='244B9433D2'><pre id='244B9433D2'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:388
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          I was wrong about Geron's blood cancer drug. Now, is it a takeover target?
          I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

          MollyFerguson/STATIwaswrongaboutGeron.Foryears,I’vebelieved—anddeclaredpublicly—thatGeron’sefforttod

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          5 to watch: Tech startups trying to solve health care's staffing crisis

          AdobeThreeyearsafterthepandemicupendedthehealthcareworkforce,hospitalstaffingisstillatopconcernforho